In addition, the presence of epitopes identified by HLA class I enables the construct to eliminate hepatitis B-infected cells through the induction of cytotoxic T cells (CD8+ T cells) and related mechanisms such as IFN-γ, perforin, and granzyme, so it can cover chronic hepatitis B patients (therapeutic effect). The gene discussed is PRF1; the disease is chronic hepatitis B virus infection.